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although less so initially to children and parents. It involves a
general anaesthetic, surgical placement of a permanent device
that can erode fragile skin, ongoing maintenance and a signifi-
cant adjustment in body image. Is it worthwhile? The systematic
review in the current issue of the British Journal of Dermatology by
Zidorio et al.1 addresses this question.
Evaluation of therapy in this complex, heterogeneous, rare
disease is difficult. There are no randomized controlled trials
of GTT in EB: the seven suitable studies selected from a litera-
ture trawl of 641 were case series. Most involved children
with RDEB and the authors included only studies providing
anthropometric data and patient- or carer-reported outcomes.
They conclude that nutritional status usually, but not always,
improves. Interestingly, some patients report better life quality
even when growth parameters have worsened, perhaps reflect-
ing the extreme burden of maintaining oral intake.2 Effects on
skin blistering, healing and activity levels are hard to quantify
and are rarely documented. Complications led to GTT removal
in 10% of patients. Unanswered questions include optimum
diet and timing: should it be placed before or after malnutri-
tion becomes a problem?
Surgical technique was not covered in this review, so failed
procedures and immediate complications would not have been
picked up. Endoscopic GTT placement risks mucosal damage,
while placement via a laparotomy is invasive and likely to be
complicated by chronic leakage. A laparoscopic approach has
been used successfully.3
Professionals managing EB need to share experience and
collect consistent data on procedures, complications, nutri-
tional status and EB-related quality of life. This can be
achieved only if those managing patients with EB consult with
expert centres, which in turn should collaborate.4 The organi-
zations Debra International and EBClinet are leading the way
in developing clinical practice guidelines.5 The U.K. has the
unique advantage of a National Health Service and national
Highly Specialized Service for EB: four of the seven studies
came from U.K. centres but even these were not ideal. The
newly established European Reference Network for Rare and
Low Prevalence Complex Disease,6 with a specific sub-the-
matic group for EB, offers exciting opportunities for collabora-
tive research, which patients and professionals sorely need.
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In this issue of the BJD, Brass and colleagues report the results
of a pilot study in which they explore the feasibility of per-
forming a large randomized controlled trial (RCT) comparing
psoralen–ultraviolet A (PUVA) and narrowband ultraviolet B
(NBUVB) for the treatment of chronic palmar hand eczema.1
It is very important that pilot studies are carried out, both
financially and methodically. A full-scale RCT will ideally be
performed only if its design proves feasible in a pilot. Poten-
tial flaws can be identified and dealt with, increasing the
chance of performing a meaningful definitive study with prac-
tical implications. However, one should be very careful about
the interpretation of efficacy data from pilot studies. Because
pilot studies often contain the first structured assessment of
the effect of an intervention, no robust sample-size calculation
can be performed a priori. No sound conclusions can be made
based on an insufficient sample size. One can often only really
draw conclusions regarding feasibility.2
Brass et al.1 venture to make some cautious statements on
efficacy outcomes. They conclude that both PUVA and NBUVB
improve the severity of chronic palmar hand eczema. How-
ever, a few considerations put this conclusion in a different
light.
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The primary efficacy outcome measure used in the study is
a Physician Global Assessment (PGA) that is used in a large
placebo-controlled trial with the retinoid alitretinoin in hand
eczema.3 This PGA incorporates not only objective signs like
fissures and erythema, but also the subjective (patient-
reported) items ‘pain’ and ‘itch’, which influence the severity
score, making it hard to reproduce this outcome and making
proper comparison between patients and between studies dif-
ficult. The authors argue that a more objective outcome like
the Hand Eczema Severity Index (HECSI) might be a preferable
alternative.4 Although true, it should be noted that this instru-
ment needs to be validated more extensively before using it as
primary efficacy outcome in trials. Furthermore, this pilot
studied only patients with palmar hand eczema. A measure-
ment instrument for the severity of solely palmar hand eczema
has not yet been developed.
It is strongly recommended to patch test all patients with
chronic hand eczema in routine daily practice.5 No patch test-
ing was performed prior to this pilot. Because patients with
hand eczema frequently have allergic contact dermatitis it is
vital to take this into account.6 Patch testing will reduce the
bias of inclusion of patients into studies while they still have
major exposure to contact allergens that might be highly rele-
vant for the severity of their hand eczema.
On the subject of feasibility, the authors see some issues. A
large sample size will be needed for the definitive trial, while
the rise of systemic therapy may lead to a reduced demand
for phototherapy. Results of the ongoing ALPHA trial, compar-
ing PUVA with alitretinoin for uncontrolled severe chronic
hand eczema, will significantly influence whether there will
be a need for a full-scale trial comparing PUVA with NBUVB.7
If such a need does arise, processing the issues mentioned
above, along with the limitations that the authors state in their
discussion will contribute to the design of a more comprehen-
sive and meaningful clinical trial.
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Liver fibrosis is a wound-healing response that occurs sec-
ondary to insults from hepatocyte lipid accumulation, inflam-
mation and exposure to toxins, such as methotrexate and
alcohol. A 2017 population-based study (people with psoria-
sis: n = 197 130)1 supported what other studies have previ-
ously shown: people with severe psoriasis are more likely to
have liver fibrosis and cirrhosis than age-, sex- and BMI
matched controls in the general population.2,3
Liver fibrosis is a multifactorial disease; therefore, in human
studies it will always be a challenge to disentangle the relative
weighting of multiple potential risks (burden of inflammation,
alcohol, obesity) on fibrosis development and progression.
One strength of animal studies is the ability to investigate the
impact of one risk alone.
Does psoriasis cause liver fibrosis? In this issue of the BJD,
Vasseur et al.4 publish data to suggest that, in mice, cutaneous
inflammation induced by repetitive applications of imiqui-
mod-containing Aldara cream is associated with the develop-
ment of hepatitis and liver fibrosis. (In mice both the vehicle
in Aldara and imiquimod contribute to inflammation.)
Vasseur et al. compared two groups of mice (n = 10 mice/
group). The first group were exposed to Aldara over 9 weeks;
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